TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SK Hynix Shares Fall as Workers Reject Wage Deal 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Tesla Raises Cybertruck Prices by $5,000 in US 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Add as a preferred source on Google
VANCOUVER, British Columbia, May 02, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Deutsche Bank 43rd Annual Healthcare Conference in Boston on Wednesday, May 9th 2018.
Aquinox Presentation Details
Date: Wednesday, May 9th 2018
Time: 6:20 am Pacific Time / 9:20 am Eastern Time
Location: Boston, MA – Intercontinental Hotel Boston
A live webcast and archive of the event will be available at:
https://edge.media-server.com/m6/p/oiye7bcp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
